Global Leading Market Research Publisher QYResearch announces the release of its latest report “Infectious Particles Titration – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Infectious Particles Titration market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Infectious Particles Titration was estimated to be worth US$ 6509 million in 2025 and is projected to reach US$ 14170 million, growing at a CAGR of 11.9% from 2026 to 2032.
Infectious particles titration refers to a set of quantitative analytical methods used to determine the concentration of infectious viral particles (as opposed to total viral particles, which may include non-infectious or defective forms) in a sample. It is a critical procedure in virology, vaccine development, gene therapy, and biologics manufacturing, ensuring accurate dosing, product quality, and biosafety.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097145/infectious-particles-titration
1. Industry Pain Points and the Shift Toward Accurate Viral Vector Quantification
Gene therapies (AAV, lentivirus), oncolytic viruses, and viral vaccines require precise quantification of infectious particles to ensure potency and patient safety. Total particle counts (e.g., viral genome copies by qPCR, capsid protein by ELISA) overestimate functional titer, as they include empty capsids or defective particles. Infectious particles titration addresses this by measuring only replication-competent or functional viral units (plaque-forming units, TCID50, focus-forming units). For gene therapy developers, vaccine manufacturers, and CDMOs, these assays are essential for viral vector quantification, gene therapy potency release, and vaccine lot release compliance (FDA, EMA).
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global infectious particles titration market was valued at US$ 6.509 billion in 2025 and is projected to reach US$ 14.170 billion by 2032, growing at a CAGR of 11.9%. Market hyper-growth is driven by three factors: expanding gene therapy pipeline (1,000+ clinical trials), increasing viral vaccine manufacturing (COVID-19, influenza, RSV), and regulatory requirements for infectious titer in lot release (FDA, EMA, ICH Q5A).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four explosive developments:
- AAV gene therapy potency assays: FDA guidance (2025) requires infectious titer (e.g., TCID50) for AAV lot release, driving 25% growth in outsourced testing.
- High-throughput automation: New automated plaque counting systems (Thermo Fisher, Charles River) reduced turnaround time from 2 weeks to 5 days.
- Cell-based potency assay expansion: TCID50 and focus-forming assays (FFA) replaced traditional plaque assays for lentivirus and AAV due to faster results (3-5 days vs. 7-10 days).
- Chinese CRO emergence: GenScript, Creative Biolabs, and Vigene Biosciences expanded infectious titration capacity, capturing Asia-Pacific gene therapy market share at 20-30% below Western pricing.
4. Competitive Landscape and Key Suppliers
The market includes global CROs and specialized viral testing laboratories:
- Thermo Fisher Scientific (US), Charles River Laboratories (US), Catalent (US), Lonza (Switzerland), GenScript (China), Viroclinics (Netherlands), Virapur (US), Vigene Biosciences (US/China), Creative Biolabs (US/China), Avance Biosciences (US), Takara Bio (Japan).
Competition centers on three axes: assay sensitivity (PFU/mL or TCID50/mL), turnaround time (days), and regulatory expertise (FDA/EMA).
5. Segment-by-Segment Analysis: Type and Application
By Assay Type
- Plaque Test (PFU) : Gold standard for lytic viruses (adenovirus, oncolytic HSV). Slower (7-14 days), labor-intensive. Declining share (~40%).
- TCID50 (Tissue Culture Infectious Dose) : Most common for non-lytic viruses (AAV, lentivirus). Faster (5-7 days), semi-automated. Fastest-growing segment (CAGR 13%), account for ~50% of market.
- Hemagglutination Test: For influenza virus. Rapid (1-2 days), lower sensitivity. ~5% of market.
- Others: Focus-forming assay (FFA), flow cytometry-based. ~5% of market.
By Application
- Cell and Gene Therapy: Largest and fastest-growing segment (~50% of market). AAV, lentivirus, adenovirus, oncolytic virus potency testing. CAGR 13%.
- Vaccine Development and Production: (~30% of market). Influenza, polio, COVID-19, RSV. Lot release testing.
- Virology Research: (~15% of market). Academic and pharma R&D.
- Others: Viral safety testing, environmental monitoring. ~5% of market.
User case – AAV gene therapy potency release: A gene therapy company (AAV8 for hemophilia) outsourced infectious titration (TCID50) to Charles River. Three lots tested in parallel (5-day turnaround). Infectious titer: 1.2-1.8e9 TCID50/mL, consistent with historical data. Lot release completed, enabling clinical trial supply. In-house assay development would have required 6+ months.
6. Exclusive Insight: Infectious Titration Methods for Viral Vectors
| Method | Virus Type | Principle | Turnaround | Sensitivity | Reproducibility |
|---|---|---|---|---|---|
| Plaque assay (PFU) | Lytic (AdV, HSV) | Clear zone in cell monolayer | 7-14 days | High | Moderate (operator dependent) |
| TCID50 | Non-lytic (AAV, LV) | Cytopathic effect (CPE) endpoint | 5-7 days | High | High (automated reading) |
| Focus-forming assay (FFA) | Non-lytic | Immunostaining of viral foci | 3-5 days | Very high | High |
| Flow cytometry | GFP-encoding vectors | GFP+ cell counting | 2-3 days | High | Very high |
| qPCR (total genome) | All viruses | DNA/RNA quantification | 1-2 days | Very high | Very high (but measures total, not infectious) |
Technical challenge: Infectious titer for AAV requires helper virus (adenovirus or herpesvirus) to replicate, complicating assay standardization. TCID50 for AAV involves:
- Serial dilution of AAV vector
- Co-infection with helper virus (Ad5 or HSV)
- Incubation (5-7 days)
- CPE scoring (automated or manual)
- Spearman-Kärber calculation (TCID50/mL)
User case – AAV TCID50 automation: A CDMO automated AAV TCID50 using high-content imaging (Thermo Fisher CellInsight). CPE scoring reduced from 2 hours (manual) to 15 minutes (automated). Inter-operator variability decreased from 30% to 10%. Turnaround: 6 days.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (45% share, CAGR 12%). US (Thermo Fisher, Charles River, Catalent, Avance, Vigene, Virapur). Strong gene therapy pipeline.
- Europe: Second-largest (30% share, CAGR 11.5%). Switzerland (Lonza), Netherlands (Viroclinics). Strong vaccine manufacturing.
- Asia-Pacific: Fastest-growing region (CAGR 14%). China (GenScript, Creative Biolabs), Japan (Takara Bio). Cost-effective CRO services.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The infectious particles titration market is positioned for explosive growth through 2032, driven by gene therapy expansion, vaccine manufacturing, and regulatory requirements for potency testing. Stakeholders—from biopharma companies to CROs—should prioritize TCID50 and FFA for AAV/lentivirus, automation for reproducibility, and regulatory expertise for lot release. By enabling viral vector quantification and gene therapy potency assessment, infectious particles titration is essential for product quality and patient safety.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
